PALM BEACH, Florida, February 14, 2017 /PRNewswire/ --
Cannabinoid (CBD) Products, Therapies and Treatments continueto advance through research and development breakthroughs, prompting strong forecast for 2017 performance. Clinical studies in which a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) were used to treat patients continue to identify new
Vinergy Resources Ltd (OTCQB: VNNYF) (CSE:VIN), in conjunction with its proposed acquisition of MJ Biopharma (announced December 14, 2016) is pleased to announce a major breakthrough while conducting research and development on oral cannabinoid complex (Tetrahydrocannabinol (THC), Cannabidiol (CBD), Cannabinol (CBN) and Terpenes) delivery strips and controlled time release capsule technology. This novel approach will be the basis for several products where water or saliva is the catalyst used to activate the carrier for delivery and absorption of the cannabinoid complex into the body. Read this and more news for Vinergy Resources at: http://marketnewsupdates.com/news/vnnyf.html
This unique approach forms the basis for a fundamentally new technology and product category. The technology is called "BURST" due to its incredibly fast action and ability to enhance the body's absorption of various medicinal ingredients contained in the Company's products. The BURST system is built on natural botanical polymers delivering specially processed high purity cannabinoid complexes. The unique system for cannabinoid activation maintains the natural balance of THC, CBD, CBN and terpenes while preserving the maximum therapeutic effect and potentially delivering it to the body faster than any currently available delivery method. The patent pending technology allows for a more complete palatable drug delivery system that is effective and enhances the patient or user experience while intensifying flavour.
"This is a great breakthrough for us and the product line we have planned. The technology can also be utilized in our time release capsules which of course will have a slower absorption rate. We think time release capsules are extremely important as they help bridge the gap in terms of familiarity with many patients who want to switch from synthetic drugs to a natural product as a way to reduce side effects and drug," said Mr. Kent Deuters, CEO of MJ Biopharma. "We look forward to providing additional updates in the coming weeks," added Mr. Deuters. The Hemp Business Journal estimates the total U.S. CBD market will grow to $2.1 billion in consumer sales by 2020.
In other cannabis - legal marijuana market performances and developments of note include:
Canopy Growth Corporation (OTC: TWMJF) (TSX: WEED.TO) closed up on Monday at $9.92 OTC and 13.00 on the CSE trading over 800,000 shares and 6.6 Million shares respectively by the market close. Canopy Health Innovations (CHI), the recently formed research incubator partly owned by Canopy Growth Corporation (WEED.TO), has entered into a 3-year consulting agreement with EPIC Consulting Inc., the Quebec-based consulting firm of Dr. Mark Ware. Canopy Health Innovations was established to research and develop clinically ready cannabis drug formulations and delivery systems for both human and/or animal patients targeting unmet medical needs in traditional pharmaceutical markets that could be disrupted by cannabis-based options. Under a framework agreement with CHI, Canopy Growth retains the right of first refusal to commercialize all resulting intellectual property developed by CHI globally.
Cannabis Sativa, Inc. (OTCQB: CBDS) closed up over 15% on Monday at $6.58 by the market close. Cannabis Sativa, Inc., through its subsidiaries, develops, manufactures, and sells herbal based skin care products in the United States and internationally. It offers herbal based line of products, including Go Deep, a deep penetrating healing salve that reduces pain and inflammation when massaged into muscles, ligaments, tendons and more.
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) closed up over 14% on Monday at $1.35 trading over 1 Million shares by the market close. Cannabics Pharmaceuticals Inc. recently announced it will begin providing personalized cannabinoid anti-tumor tests for cancer patients. The diagnostic tests are based on liquid biopsies of patients suffering from any kind of cancer. The test uses CTC technology that collects cancer cells from patients' blood samples, and tests their sensitivity to cannabinoid compounds alongside conventional chemotherapy medicine.
OWC Pharmaceutical Research Corp. (OTCQB: OWCP) closed up over 6% on Monday at $0.695 trading over 1.3 Million shares by the market close. OWC Pharmaceutical Research Corp. engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Vinergy Resources Ltd by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information: Media Contact email: firstname.lastname@example.org +1(561)325-8757
Subscribe to our Free Newsletters!
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...
Video-electroencephalography monitoring is a diagnostic technique that records the electrical ...
Myomectomy is a surgery that is done to remove fibroids, which are non-cancerous growths of the ...View All